By Adriano Marchese

Bausch + Lomb said Monday that its laser-assisted vision correction surgery platform to treat nearsightedness was approved by the U.S. Food and Drug Administration.

The Canadian eye-health company said the FDA has approved the Teneo Excimer Laser Platform for laser-assisted in situ keratomileusis, also known as Lasik, vision correction surgery for myopia and myopic astigmatism.

Bausch + Lomb said that Teneo has been adopted in more than 50 countries around the world.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

January 08, 2024 07:26 ET (12:26 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
Bausch and Lomb (TSX:BLCO)
過去 株価チャート
から 4 2024 まで 5 2024 Bausch and Lombのチャートをもっと見るにはこちらをクリック
Bausch and Lomb (TSX:BLCO)
過去 株価チャート
から 5 2023 まで 5 2024 Bausch and Lombのチャートをもっと見るにはこちらをクリック